The 'either test positive' strategy for latent tuberculous infection before anti-tumour necrosis factor treatment

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 4, 2014, Pages 428-434

  Jung, Y J ^a   Lee, J Y ^b   Jo, K W ^a   Yoo, B ^a   Lee, C K ^a   Kim, Y G ^a   Yang, S K ^a   Byeon, J S ^a   Kim, K J ^a   Ye, B D ^a   Lee, K H ^c   Lee, S D ^a   Kim, W S ^a   Kim, D S ^a   Shim, Tae Sun ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Konkuk University   (South Korea)

^c Seoul Okjeong Elementary School   (South Korea)

Author keywords

Immune mediated inflammatory diseases; T SPOT.TB; Tuberculin skin test; Tumour necrosis factor

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; ISONIAZID; RIFAMPICIN; STEROID; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BCG VACCINATION; COMORBIDITY; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC KIT; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LATENT TUBERCULOSIS; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MYALGIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; RHEUMATOID ARTHRITIS; SOUTH KOREA; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULIN TEST; ADOLESCENT; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL PROTOCOL; EPIDEMIOLOGY; IMMUNOLOGY; INTERFERON GAMMA RELEASE ASSAY; MICROBIOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PREVALENCE; PROGNOSIS; TERTIARY CARE CENTER; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CLINICAL PROTOCOLS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; REPUBLIC OF KOREA; TERTIARY CARE CENTERS; TUBERCULIN TEST; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84897127866     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0644     Document Type: Article

References (29)

1. Keane J, Gershon S, Wise R P, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
2. Carmona L, Gómez-Reino J J, Rodríguez-Valverde V, et al. BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-1772. (Pubitemid 40852885)
3. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005; 64: 1360-1361. (Pubitemid 41206259)
4. Richeldi L, Losi M, D'Amico R, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 2009; 136: 198-204.
5. Ballew K A, Becker D M. Tuberculosis screening in adults who have received bacilli Calmette-Guérin vaccine. South Med J 1995; 88: 1025-1030.
6. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340-354. (Pubitemid 351650594)
7. Rangaka M X, Wilkinson K A, Glynn J R, et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 45-55.
8. Smith R, Cattamanchi A, Steingart K R, et al. Interferon-gamma release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Curr Opin Rheumatol 2011; 23: 377-384.
9. Singanayagam A, Manalan K, Sridhar S, et al. Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-α antagonist therapy. Thorax 2013; 68: 955-961.
10. Mazurek G H, Jereb J, Vernon A, et al., IGRA Expert Committee, Centers for Disease Control and Prevention. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010; 59: 1-25.
11. Jung Y J, Lyu J, Yoo B, et al. Combined use of a TST and the T-SPOT®.TB assay for latent tuberculosis infection diagnosis before anti-TNF-α treatment. Int J Tuberc Lung Dis 2012; 16: 1300-1306.
12. Jo KW, Woo JH, Hong Y, et al. Incidence of tuberculosis among health care workers at a private university hospital in South Korea. Int J Tuberc Lung Dis 2008; 12: 436-440. (Pubitemid 351507258)
13. Arnett F C, Edworthy S M, Bloch D A, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324. (Pubitemid 18091653)
14. van der Linden S, Valkenburg H A, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-368. (Pubitemid 14134775)
15. Lichtenstein G R, Hanauer S B, Sandborn W J; Practice Parameters Committee of American College Of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104: 465-483.
16. Oxford Immunotec. T-SPOT.TB, an aid in the diagnosis of tuberculosis infection. Abingdon, UK: Oxford Immunotec, http://www.oxfordimmunotec.com/eu/ downloads/PI-TB96-IVD-UK-V8,%20English.pdf Accessed January 2014.
17. Solovic I, Sester M, Gomez-Reino J J, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010; 36: 1185-1206.
18. Lee J Y, Choi H J, Park I N, et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J. 2006; 28: 24-30. (Pubitemid 44914256)
19. Menzies D, Dion M J, Rabinovitch B, et al. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170: 445-459.
20. Perez J, Kupper H, Spencer-Green G. Impact of screening for latent TB before initiating anti-TNF therapy in North America and Europe. Ann Rheum Dis 2005; 64 (Suppl 3): 265.
21. Canadian Tuberculosis Committee. Recommendations on interferon gamma release assays for the diagnosis of latent tuberculosis infection - 2010 update. Can Commun Dis Rep 2010; 36: 1-21.
22. Health Protection Agency UK. Health Protection Agency position statement on the use of interferon gamma release assay (IGRA) tests for tuberculosis (TB). Draft interim internal HPA guidance, October 2007. London, UK: HPA, 2008.
23. Takahashi H, Shigehara K, Yamamoto M, et al. Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration. Rheumatol Int 2007; 27: 1143-1148. (Pubitemid 47373944)
24. Kleinert S, Tony H P, Krueger K, et al. Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions. Ann Rheum Dis 2012; 71: 1791-1795.
25. Korea Centers for Disease Control and Prevention. Clinical Practice Guidelines for Tuberculosis. Seoul, Korea: Korea Centers for Disease Control and Prevention, 2011. http://www.lungkorea.org/image/mail/file-110217.pdf Accessed January 2014. [Korean]
26. Chang B, Park H Y, Jeon K, et al. Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. Clin Rheumatol 2011; 30: 1535-1541.
27. Tubach F, Salmon D, Ravaud P, et al., Research Axedon Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009: 60: 1884-1894.
28. Furst D E, Wallis R, Broder M, Beenhouwer D O. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006: 36: 159-167.
29. Kim J H, Cho S K, Han M, et al. Factors influencing discrepancies between the QuantiFERON®-TB Gold In-Tube test and the tuberculin skin test in Korean patients with rheumatic diseases. Semin Arthritis Rheum 2013; 42: 424-432.